There are multiple players in the Magic Roundabout, but are some more important than others and will different culprits turn out to have hidden meanings? You may never see Ermintrude in the same way again 😉
Without a doubt, there are multiple potential ways we can go about improving responses to cancer immunotherapy, not just in terms of targets, combination approaches, different modalities etc, but also by manipulating the tumour microenvironment or thinking about directing different immune cells in positive ways.
In our latest review, we look at one area where emerging work appears to bearing fruit as multiple groups suddenly get one of those, a-ha! moments.
It’s not just happening in one tumour type either, nor is it limited to one type of therapy or modality, which makes it all the more intriguing to think about.
We heard about one example of this mechanism last year and now it’s time to explore things in more detail. This also means companies quick on the uptake could well take advantage ahead of their competitors.
To learn more from our oncology coverage and get a heads up on our latest analysis, commentary, and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
For today’s post, we’ve curated our individual highlights from the tsunami of data that flew thick and fast yesterday between science sessions, oral presentations and poster hall gems.
There were some pleasant surprises in the mix, to be sure, plus the weather brightened up immeasurably!
Yesterday’s lunch time ASH Dash was quieter than usual
Having whittled the number of trial highlights for review and critique down to thirteen key insights and learnings, what made our joint list?
To find out more, check out the post below!
To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.